Cyclopharm (ASX:CYC) - Aktienkurs, Nachrichten und Analyse

CYC Aktienübersicht

Cyclopharm Limited produziert und vertreibt medizinische Geräte und Radiopharmazeutika im asiatisch-pazifischen Raum, in Europa, Kanada und international.

Über das Unternehmen

CYC grundlegende Analyse
Schneeflocken-Punktzahl
Bewertung	4/6
Künftiges Wachstum	5/6
Vergangene Leistung	0/6
Finanzielle Gesundheit	5/6
Dividenden	0/6

Belohnungen

85.9% unter unserer Schätzung des beizulegenden Zeitwerts gehandelt

Prognostiziertes Gewinnwachstum 94.87% pro Jahr

Risikoanalyse

Die Aktionäre wurden im vergangenen Jahr verwässert

Cyclopharm Limited Wettbewerber

Optiscan Imaging

ASX:OIL

AU$158.7m

ImpediMed

ASX:IPD

AU$117.3m

SomnoMed

ASX:SOM

AU$86.4m

Austco Healthcare

ASX:AHC

AU$88.4m

Preisentwicklung & Leistung

Übersicht über alle Höchststände, Veränderungen und Kursrückgänge für Cyclopharm
Historische Aktienkurse
Aktueller Aktienkurs	AU$1.47
52-Wochen-Hoch	AU$3.15
52-Wochen-Tief	AU$1.35
Beta	0.70
11 Monat Veränderung	6.52%
3 Monate Veränderung	-13.02%
1 Jahr Veränderung	-48.06%
33 Jahre Veränderung	-9.26%
5 Jahre Veränderung	22.50%
Veränderung seit IPO	-21.60%

Aktuelle Nachrichten und Updates

Recent updates

What You Can Learn From Cyclopharm Limited's (ASX:CYC) P/SAfter Its 26% Share Price Crash

Oct 28

Here's Why We're Not At All Concerned With Cyclopharm's (ASX:CYC) Cash Burn Situation

Mar 02

We Think Cyclopharm (ASX:CYC) Can Afford To Drive Business Growth

Oct 22

Cyclopharm Limited's (ASX:CYC) Analyst Just Slashed This Year's Estimates

Jun 29

Shareholders Will Probably Hold Off On Increasing Cyclopharm Limited's (ASX:CYC) CEO Compensation For The Time Being

Apr 27

Rainbows and Unicorns: The Cyclopharm Limited (ASX:CYC) Analyst Just Became A Lot More Optimistic

Mar 01

Cyclopharm (ASX:CYC) Has Rewarded Shareholders With An Exceptional 401% Total Return On Their Investment

Feb 07

Is Cyclopharm Limited (ASX:CYC) Popular Amongst Insiders?

Jan 02

We're Not Very Worried About Cyclopharm's (ASX:CYC) Cash Burn Rate

Dec 06

Aktionärsrenditen

	CYC	AU Medical Equipment	AU Markt
7D	2.1%	0.3%	0.3%
1Y	-48.1%	12.3%	16.1%

Rendite im Vergleich zur Industrie: CYC unter dem Niveau der Branche Australian Medical Equipment , die im vergangenen Jahr eine Rendite von 13.1% erzielte.

Rendite vs. Markt: CYC hinter dem Markt Australian zurück, der im vergangenen Jahr eine Rendite von 11.2 erzielte.

Preisvolatilität

Is CYC's price volatile compared to industry and market?
CYC volatility
CYC Average Weekly Movement	5.6%
Medical Equipment Industry Average Movement	9.5%
Market Average Movement	8.9%
10% most volatile stocks in AU Market	17.0%
10% least volatile stocks in AU Market	3.6%

Stabiler Aktienkurs: CYC hat in den letzten 3 Monaten keine nennenswerten Preisschwankungen aufgewiesen.

Volatilität im Zeitverlauf: CYCDie wöchentliche Volatilität (10%) ist im vergangenen Jahr stabil geblieben.

Über das Unternehmen

Gegründet	Mitarbeiter	CEO	Website
1986	87	James McBrayer	www.cyclopharm.com

Cyclopharm Limited produziert und vertreibt medizinische Geräte und Radiopharmazeutika im asiatisch-pazifischen Raum, in Europa, Kanada und international. Das Unternehmen ist in den Segmenten Technegas und Molecular Imaging tätig. Das Segment Technegas bietet Diagnosegeräte und Verbrauchsmaterialien an, die von Ärzten zum Nachweis von Lungenembolien verwendet werden.

Cyclopharm Limited's Grundlagenzusammenfassung

Wie verhalten sich die Erträge und Einnahmen von Cyclopharm im Vergleich zum Marktanteil des Unternehmens?
CYC grundlegende Statistiken
Marktanteil	AU$163.37m
Gewinn(TTM)	-AU$9.32m
Umsatz(TTM)	AU$24.06m

6.8x

Kurs-Umsatz-Verhältnis

-17.5x

Kurs-Gewinn-Verhältnis

Ist CYC zu teuer?

Siehe Fair Value und Bewertungsanalyse

Erträge & Einnahmen

Wichtige Rentabilitätsstatistiken aus dem letzten Ergebnisbericht (TTM)
CYC Gewinn- und Verlustrechnung (TTM)
Einnahmen	AU$24.06m
Kosten der Einnahmen	AU$10.23m
Bruttogewinn	AU$13.82m
Sonstige Ausgaben	AU$23.14m
Umsatz	-AU$9.32m

Zuletzt gemeldete Gewinne

Jun 30, 2024

Datum des nächsten Gewinnberichts

k.A.

Gewinn per Aktie (EPS)	-0.084
Bruttomarge	57.47%
Nettogewinnspanne	-38.72%
Schulden/Eigenkapital-Verhältnis	0%

Wie hat sich CYC auf lange Sicht entwickelt?

Historische Performance und Vergleiche

CYC Aktienübersicht

Belohnungen

Risikoanalyse

Cyclopharm Limited Wettbewerber

ASX:OIL

AU$158.7m

ASX:IPD

AU$117.3m

ASX:SOM

AU$86.4m

ASX:AHC

AU$88.4m

Preisentwicklung & Leistung

Aktuelle Nachrichten und Updates

Consensus revenue estimates fall by 13%

First half 2024 earnings released: AU$0.078 loss per share (vs AU$0.032 loss in 1H 2023)

Forecast breakeven date pushed back to 2026

New minor risk - Shareholder dilution

Cyclopharm Limited has completed a Follow-on Equity Offering in the amount of AUD 20.000001 million.

Cyclopharm Limited has filed a Follow-on Equity Offering in the amount of AUD 2 million.

Recent updates

Consensus revenue estimates fall by 13%

First half 2024 earnings released: AU$0.078 loss per share (vs AU$0.032 loss in 1H 2023)

Forecast breakeven date pushed back to 2026

New minor risk - Shareholder dilution

Cyclopharm Limited has completed a Follow-on Equity Offering in the amount of AUD 20.000001 million.

Cyclopharm Limited has filed a Follow-on Equity Offering in the amount of AUD 2 million.

New minor risk - Market cap size

Consensus revenue estimates fall by 14%

Cyclopharm Limited, Annual General Meeting, May 27, 2024

Full year 2023 earnings: EPS exceeds analyst expectations

Cyclopharm Limited Appoints John Wigglesworth to its Board as Non- Executive Director

Consensus EPS estimates fall by 11%

CEO, MD exercised options to buy AU$402k worth of stock.

What You Can Learn From Cyclopharm Limited's (ASX:CYC) P/SAfter Its 26% Share Price Crash

Forecast breakeven date pushed back to 2025

First half 2023 earnings released: AU$0.032 loss per share (vs AU$0.028 loss in 1H 2022)

Cyclopharm Limited Declares Unfranked Interim Dividend for the Six Months Ended June 30, 2023, Payable on 11 September 2023

Consensus estimates of losses per share improve by 13%

Is Cyclopharm Limited (ASX:CYC) Trading At A 25% Discount?

Companies Like Cyclopharm (ASX:CYC) Are In A Position To Invest In Growth

Consensus EPS estimates fall by 153%

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Cyclopharm Limited Announces Dividend for A Period of Six Months Ended December 31, 2022, Payable on April 4 2023

Less than half of directors are independent

Companies Like Cyclopharm (ASX:CYC) Can Afford To Invest In Growth

Less than half of directors are independent

Cyclopharm Limited Appoints Gregory King as A Non-Executive Director

Cyclopharm Limited Appoints Kevin Barrow as A Nonexecutive Director

First half 2022 earnings released: AU$0.028 loss per share (vs AU$0.045 loss in 1H 2021)

Cyclopharm Limited Declares an Unfranked Dividend for the Half Year Ended June 30, 2022, Payable on 12 September 2022

Consensus revenue estimates increase by 10%

Cyclopharm Limited Announces Independent Multicentre Study Highlights the Benefits of Technegas in Diagnosing Pulmonary Embolism in Growing Covid-19 Patient Population

Cyclopharm Limited Provides Sales Guidance for the Half Year Ended 30 June 2022

Companies Like Cyclopharm (ASX:CYC) Can Afford To Invest In Growth

Cyclopharm Limited Announces Technegas Used in Diagnosing Long COVID

Full year 2021 earnings: Revenues exceed analyst expectations

Analyst Forecasts For Cyclopharm Limited (ASX:CYC) Are Surging Higher

Here's Why We're Not At All Concerned With Cyclopharm's (ASX:CYC) Cash Burn Situation

Consensus revenue estimates increase by 14%

Forecast to breakeven in 2024

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Cyclopharm Limited Announces Dividend for Period of Six Months Ended December 31, 2021, Payable on April 12, 2022

Cyclopharm Limited Provides Earnings Guidance for the Full Year 2021

Less than half of directors are independent

We Think Cyclopharm (ASX:CYC) Can Afford To Drive Business Growth

First half 2021 earnings released: AU$0.045 loss per share (vs AU$0.074 loss in 1H 2020)

Cyclopharm Limited Provides Unaudited Revenue Guidance for the First Half of 2021

Cyclopharm Limited's (ASX:CYC) Analyst Just Slashed This Year's Estimates

Consensus revenue estimates fall to AU$16.5m

Shareholders Will Probably Hold Off On Increasing Cyclopharm Limited's (ASX:CYC) CEO Compensation For The Time Being

Full year 2020 earnings released: AU$0.079 loss per share (vs AU$0.043 loss in FY 2019)

Cyclopharm Limited provides Confirmation of Technegas USFDA Timetable

Analysts increase revenue estimates to AU$18.6m

Cyclopharm Limited, Annual General Meeting, May 04, 2021

Rainbows and Unicorns: The Cyclopharm Limited (ASX:CYC) Analyst Just Became A Lot More Optimistic

Full year 2020 earnings released: AU$0.079 loss per share (vs AU$0.043 loss in FY 2019)

Revenue beats expectations, earnings disappoint

Cyclopharm Limited Provides Update on USFDA Approval to Distribute Technegas in the USA in 2021

Cyclopharm (ASX:CYC) Has Rewarded Shareholders With An Exceptional 401% Total Return On Their Investment

Erträge & Einnahmen